Trump Order Fast-Tracks Review of Psychedelic Therapies: What to Know

Trump’s order directed federal agencies to provide paths for greater access and faster research.

(L-R) FDA Commissioner Marty Makary, Health and Human Services Secretary Robert F. Kennedy Jr., US media personality Joe Rogan, W. Bryan Hubbard, CEO of Americans for Ibogaine, and former Navy SEAL Marcus Luttrell look on as U.S. President Donald Trump signs an executive order in the Oval Office on April 18, 2026. The executive order aims to further U.S. federal medical research and clinical trials for certain psychedelic drugs. Jim WATSON / AFP via Getty Images

President Donald Trump signed an executive order on April 18 to expand access to psychedelic drugs as treatments for Americans with mental health disorders.

The order directed federal agencies to accelerate the process of research and approval for psychedelics, including ibogaine, a plant-derived compound currently classified as a Schedule I substance.